ImmunityBio, Inc. (IBRX)
$9.80-3.16%Close
BUYRECOVERY · day 47
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV37.5%–194.0%
- Market cap
- $10.3B
- Beta
- 0.13
- P/E (TTM)
- -10.07
- IV-%ile
- 42
- IV ATM
- 91.6%
- Short % float
- 109.01%
- Days to cover
- 8.9
- SI change
- -1.1%
- 1W
- +1.14%
- 1M
- +17.08%
- vs SPY 1W
- +1.27%
- vs SPY 1M
- +14.58%
Industry peers
FMP comparable companies · ranked by market cap
- MRNABUYModerna, Inc.$85.8BRECOVERYQ 36$216.25+1.17%
- BNTXSELLBioNTech SE$22.4BCRISISQ 35$89.01-7.13%
- IOVABUYIovance Biotherapeutics, Inc.$6.5BRECOVERYQ 9$14.50-0.41%
- LEGNSELLLegend Biotech Corporation$3.3BRECOVERYQ 2$17.88+0.45%
- VIRBUYVir Biotechnology, Inc.$1.8BRECOVERYQ 12$10.61-6.11%
- IMCRSELLImmunocore Holdings plc$1.4BBEARQ 1$27.82-4.20%
- IMTXSELLImmatics N.V.$916MCRISISQ 5$6.83-5.27%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on IBRX?
- LOPJLB’s latest quantitative signal on ImmunityBio, Inc. (IBRX) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is IBRX in?
- ImmunityBio, Inc. (IBRX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does ImmunityBio, Inc. (IBRX) do?
- ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel an…